IDEAYA Biosciences, Inc. (IDYA) 

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Show less

Over the last 12 months, insiders at IDEAYA Biosciences, Inc. have bought $0 and sold $20.31M worth of IDEAYA Biosciences, Inc. stock.

On average, over the past 5 years, insiders at IDEAYA Biosciences, Inc. have bought $1.72M and sold $9.33M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 5,062 shares for transaction amount of $67,408 was made by BVF PARTNERS L P/IL (10 percent owner) on 2020‑06‑30.